Finafloxacin Drug Asset Due Diligence Report 2026

This Finafloxacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Finafloxacin can convert its Small molecule drug profile and Bacterial Top II x Bacterial top IV biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Finafloxacin (query alias: finafloxacin)
Modality / target	Small molecule drug; Bacterial Top II x Bacterial top IV; Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors
Highest global status	Approved
Originator	Alcon AG
Active developers	Fonseca Biosciences LLC

The MCP disease footprint includes Acute otitis media. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT02432105	Phase 3	Completed	470	Percentage of Subjects With Sustained Clinical Cure at Day 8
NCT02436304	Phase 3	Completed	404	Percentage of Subjects With Sustained Clinical Cure at Day 8
NCT01928433	Phase 2	Completed	225	Number of Participants With Clinical and Microbiological Response

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections

Phase 2; n=193; evaluation: Positive. Reported fields: CPR(10-day) = 57 % ; CPR(10-day) = 68 %

Pharmacokinetics of intravenous finafloxacin in healthy volunteers

Phase 1; n=58; evaluation: not stated. Reported fields: Maximum plasma concentrations = 2.56 - 20.2 μg/ml

A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.

Phase 2; n=225; evaluation: not stated. Reported fields: Number of Participants With Clinical and Microbiological Response = 46 Participants ; Number of Participants With Clinical and Microbiological Response = 35 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Finafloxacin addresses Acute otitis media. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-12-11	Fonseca Biosciences Secures Exclusive US Rights to XTORO® (finafloxacin otic suspension) 0.3% to Treat Swimmer’s Ear	Withdrawn	Financial terms not disclosed
2018-07-31	MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Finafloxacin for use in the treatment of urinary tract infections”. The milestone feed surfaced a patent-application signal described as “Compositions comprising finafloxacin and tris”. The milestone feed surfaced a patent-application signal described as “Finafloxacin suspension compositions”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO